Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.09.2013 | short review

Biosimilars versus generics: scientific basics and clinical implications

verfasst von: Harald H. Sitte, MD, Michael Freissmuth

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Generic drugs contain the identical chemical copy of their cognate originator drug’s active ingredient and this can be proven by their physicochemical properties and the structural identity. A more complex situation is given when it comes to biological drugs, where identical copies cannot be produced. Hence, similar to the approval of the originator biological drug, great care must be employed when approving biosimilar protein drugs. Furthermore, this needs to be continued after the entrance of biological/biosmilar drugs into the market: rigorous pharmacovigilance during their application is the key and the close surveillance of their production is mandatory. In this review, we will highlight the differences between generic and biosimilar drugs and point out what healthcare professionals need to know.
Vorheriger Artikel Cancer-associated venous thromboembolism: risk assessment, prevention, and treatment
Nächster Artikel Controversial issues in the therapy of oesophageal carcinoma
Literatur
1.
2.
Verbeeck RK, Musuamba FT. The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action. J Pharm Pharm Sci. 2012;15:376–88.PubMed
3.
4.
5.
6.
Nightingale SL, Morrison JC. Generic drugs and the prescribing physician. JAMA. 1987;258(9):1200–4.PubMedCrossRef
7.
8.
Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300:2514–26.PubMedCrossRef
9.
Gagne JJ, Avorn J, Shrank WH, Schneeweiss S. Refilling and switching of antiepileptic drugs and seizure-related events. Clin Pharmacol Ther. 2010;88:347–53.PubMedCrossRef
10.
Sauerborn M, Brinks V, Jiskoot W, Schellekens H. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci. 2010;31:53–9.PubMedCrossRef
11.
Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018–28.PubMedCrossRef
12.
Gibbs JP. Prediction of exposure-response relationships to support first-in-human study design. AAPS J. 2010;12:750–8.PubMedCrossRef
13.
Brockmayer C, Seidel A. Binocrit: assessment of quality, safety and efficacy of biopharmaceuticals EJHP Practice. 2009;15(2):34–40.
14.
Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R.Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29:310–2.PubMedCrossRef
15.
Espinosa-de la Garza CE, Perdomo-Abúndez FC, Padilla-Calderón J, Uribe-Wiechers JM, Pérez NO, Flores-Ortiz LF, Medina-Rivero E. Analysis of recombinant monoclonal antibodies by capillary zone electrophoresis. Electrophoresis. 2013;34:1133–40.PubMedCrossRef
16.
Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol. 2004;22:1383–91.PubMedCrossRef
17.
Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;72:315–8.PubMedCrossRef
18.
Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol. 2004;251(2):II4–9.PubMed
19.
Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio SM, Raisch DW, Evens AM, Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Rossert J, Casadevall N. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004;30(351):1403–8.CrossRef
20.
Macdougall IC, Roger SD, Francisco A de, Goldsmith DJ, Schellekens H, Ebbers H, Jelkmann W, London G, Casadevall N, Hörl WH, Kemeny DM, Pollock C. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int. 2012;81:727–32.PubMedCrossRef
21.
Pollock C, Johnson DW, Hörl WH, Rossert J, Casadevall N, Schellekens H, Delage R, De Francisco A, Macdougall I, Thorpe R, Toffelmire E. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol. 2008;3:193–9.PubMedCrossRef
22.
Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, Eckardt KU. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009;361:1848–55.PubMedCrossRef
23.
Shimizu H, Saitoh T, Ota F, Jimbo T, Tsukada Y, Murakami H, Nojima Y. Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin. Acta Haematol. 2011;126:114–8.PubMedCrossRef
24.
Schellekens H, Jiskoot W. Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol. 2006;24:613–4.PubMedCrossRef
25.
Seidl A, Hainzl O, Richter M, Fischer R, Böhm S, Deutel B, Hartinger M, Windisch J, Casadevall N, London GM, Macdougall I. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res. 2012;29:1454–67.PubMedCrossRef
26.
Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonen E, Ho K, Moreau A, Narayanan G, Kruse NA, Reichmann G, Thorpe R, Aerts L van, Vleminckx C, Wadhwa M, Schneider CK. Biosimilars: what clinicians should know. Blood. 2012;120:5111–7.PubMedCrossRef
27.
28.
Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol. 2008;26:985–90.PubMedCrossRef
29.
Brinks V, Jiskoot W, Schellekens H. Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res. 2011;28:2379–85.PubMedCrossRef
30.
31.
Declerck PJ. Biosimilar monoclonal antibodies: a science-based regulatory challenge. Expert Opin Biol Ther. 2013;13:153–6.PubMedCrossRef
Metadaten
Titel
Biosimilars versus generics: scientific basics and clinical implications
verfasst von
Harald H. Sitte, MD
Michael Freissmuth
Publikationsdatum
01.09.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0094-8

Weitere Artikel der Ausgabe 3/2013

Aggressive lymphoma at ASH 2012: new standards and new perspectives

  • short review

ASH 2012 update chronic lymphocytic leukemia—the best is yet to come

  • short review

Georgia on my mind: multiple myeloma highlights at ASH 2012

  • short review

Personalized medicine for breast cancer: dream or reality?

  • review

Philadelphia-negative myeloproliferative neoplasms at the 2012 ASH meeting: a personal summary

  • short review

Molecular therapies of colorectal cancer: where will we go from here?

  • short review